Lilly Weight Loss Drug: Approved Indications and Biology

Last reviewed: May 12, 2026 Last updated: May 12, 2026

Written by: Jay Hastings , CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance. His work has included scaling healthcare startups, leading CLIA lab integrations, and helping expand consumer access to precision health tools.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This article is part of the PlexusDx Education Hub, our library of evidence-based guidance on GLP-1 therapies, weight-management protocols, and the genetics behind metabolic decisions. Browse all Peptides & GLP-1 education for more.

"Lilly weight loss drug" is a which-product question at heart. Eli Lilly makes several GLP-1-class medications, but only some carry a chronic weight-management indication, and the distinction matters for coverage and for what a clinician can prescribe. Below, we sort out which Lilly product is the weight-management one, the class biology behind it, and the genetic terrain underneath.

Which Lilly product is the weight-management one

Among Lilly's GLP-1-class portfolio, Zepbound (tirzepatide) is the product FDA-approved for chronic weight management, cleared in 2023, with an added indication for obstructive sleep apnea in adults with obesity in December 2024. The same molecule, tirzepatide, is also marketed as Mounjaro for type 2 diabetes, approved in 2022. Lilly's Trulicity (dulaglutide) is approved for type 2 diabetes, with a cardiovascular indication added in 2020, rather than for weight management.

Why the indication label matters

The FDA-approved indication determines how a product is labeled, covered, and prescribed. A tirzepatide product approved for weight management is regulated and reimbursed differently from the same molecule approved for diabetes, which is why the brand name on the box, not just the ingredient, carries practical weight.

The class biology behind the drug

Tirzepatide is the only FDA-approved GIP/GLP-1 dual agonist, a distinct strategy from Novo Nordisk's GLP-1-selective compounds such as semaglutide and liraglutide. Lilly spans both approaches, with the dual agonist in tirzepatide and a GLP-1-selective option in dulaglutide. Head-to-head data comes from trials such as SURPASS-2 (tirzepatide vs semaglutide 1 mg in type 2 diabetes) and SUSTAIN 7 (semaglutide vs dulaglutide), though direct weight-management head-to-head data remains limited.

Where investigational compounds sit

Lilly's pipeline includes orforglipron, an oral non-peptide GLP-1 receptor agonist in Phase 3, and retatrutide, a GLP-1/GIP/glucagon triple agonist in Phase 3. Retatrutide is investigational, not FDA-approved, and is not sold by PlexusDx.

Cost and safety across the class

Manufacturer list prices are broadly similar across branded products, typically $800-$1,600 per month at U.S. list as of April 2026, with savings and patient assistance programs that differ by product. All FDA-approved GLP-1 receptor agonists and GIP/GLP-1 dual agonists carry the class boxed warning for thyroid C-cell tumor risk observed in rodent studies, and are contraindicated in patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2. Common side effects are gastrointestinal, with rare serious events including pancreatitis, gallbladder events, and acute kidney injury tied to dehydration.

The genetics beneath the pathway

PlexusDx offers semaglutide and tirzepatide through its Weight Management Protocols, including the Tirzepatide Injection. Before starting any GLP-1 pathway protocol, the Precision Peptide Genetic Test analyzes 14 pathways, 49 peptides, 150+ genetic insights — including variants in FTO, GLP1R, and MC4R that shape your baseline GLP-1, appetite-regulation, and energy-balance biology. These pathway-level associations never predict response to any specific product, and the test applies through 503A compounding only.

Keep reading on PlexusDx: Tirzepatide vs Semaglutide for Weight Loss and Semaglutide Tablets for Weight Loss.

Sorting the portfolio at a glance

The quickest way to keep Lilly's products straight is by indication. Zepbound is the weight-management tirzepatide, Mounjaro is the diabetes tirzepatide, and Trulicity is a separate molecule, dulaglutide, indicated for diabetes. Same manufacturer, overlapping chemistry in the tirzepatide pair, but different labels and different approved uses.

That framing also clarifies what is not yet available. Orforglipron and retatrutide sit in Phase 3 and remain investigational, so they are not products a patient can obtain today. Keeping approved products separate from pipeline candidates avoids confusion when reading news coverage that mixes the two together.

Read this way, the Lilly weight-loss question resolves cleanly to Zepbound as the weight-management tirzepatide, with Mounjaro and Trulicity serving different approved roles. Holding that map in mind makes the category easier to follow and gives you firmer footing when you discuss options with a qualified provider who can account for your specifics.

Frequently Asked Questions

Which Lilly product is approved for weight loss?

Zepbound (tirzepatide) is Lilly's product FDA-approved for chronic weight management, cleared in 2023, with an added obstructive sleep apnea indication in December 2024. The same molecule is marketed as Mounjaro for type 2 diabetes, and Trulicity (dulaglutide) is approved for type 2 diabetes rather than weight management.

What makes tirzepatide different from other GLP-1 drugs?

Tirzepatide is the only FDA-approved GIP/GLP-1 dual agonist, engaging two receptor systems rather than one. Novo Nordisk's semaglutide and liraglutide are GLP-1-selective. SURPASS-2 and SUSTAIN 7 inform the competitive picture, though direct weight-management head-to-head comparisons remain limited across most products.

Is retatrutide a Lilly weight loss drug I can get?

No. Retatrutide is an investigational GLP-1/GIP/glucagon triple agonist in Phase 3 trials. It is not FDA-approved and is not sold by PlexusDx. Only FDA-cleared products and compounded formulations through licensed 503A pharmacies are available options to discuss with a provider.

Can genetic testing tell me if a Lilly drug will work?

No. The Precision Peptide Genetic Test does not predict response to any product. It analyzes pathway-level variants in FTO and MC4R, and TCF7L2 that shape baseline GLP-1 and energy-balance biology, offering upstream context for a provider conversation rather than a prediction of results.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance. References are included at the end of the article when scientific, medical, or health-related claims are discussed.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.